JERUSALEM — Teva Pharmaceutical Industries announced the launch of an authorized generic of Flector 1 Patch, 1.3%, in the U.S. Diclofenac epolamine topical patch, 1.3%, a non-steroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions.

“The launch of our authorized generic of Flector Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” said Brendan O’Grady, executive vice president and head of North America Commercial.

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product. With the launch of Diclofenac Epolamine Topical Patch, 1.3%, Teva now has over 16 medicines in the Analgesics and Antipyretics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) therapeutic area in the U.S.